Ozempic is changing people's skin, say plastic surgeons

Original Article ↗ Hacker News Discussion ↗

What Ozempic Is and How It’s Used

  • Some commenters note that Ozempic (semaglutide, a GLP‑1 agonist) is primarily a diabetes drug but widely used off‑label for weight loss.
  • Others outside the US/UK say they’d barely heard of it or that it’s restricted to type 2 diabetics.
  • A claim appears that millions of Americans use it, roughly half without diabetes.

Skin Changes and “Ozempic Face”

  • Several note that rapid weight loss often makes people look older: looser skin, sharper features.
  • The article’s suggestion that Ozempic causes distinct skin changes is viewed as important if true, but currently unclear.
  • Some speculate that poor diet quality plus eating less (same junk food, smaller amounts) may cause malnutrition that worsens skin and tissue quality.
  • A few propose pairing GLP‑1 drugs with skin‑care interventions (retinoids, vitamin A, collagen), while others warn about side‑effects and “pill for the pill” cascades.

Is It the Drug or Rapid Weight Loss?

  • One key quote highlighted: a surgeon claims he does not see the same facial changes in diet or surgery patients, suggesting a GLP‑1‑specific effect.
  • Others point out the article also links similar patterns to other rapid weight loss, calling the messaging internally inconsistent and possibly FUD.
  • Overall: mechanism is unresolved; correlation vs causation is explicitly questioned.

Muscle Loss, Diet Quality, and Exercise

  • Concerns that up to ~50% of lost weight on GLP‑1s can be lean mass; commenters advocate high protein intake and resistance training.
  • Others argue exercise modestly affects weight but strongly affects composition and metabolic health.
  • There is disagreement on how much exercise “matters” for fat loss vs diet and drugs.

Risk–Benefit Framing and Moral Attitudes

  • Some emphasize that obesity’s risks (diabetes complications, cardiovascular disease) dwarf cosmetic downsides like sagging skin.
  • Others see cultural hostility to “easy” pharmacologic weight loss, with moral overtones about willpower and “cheating.”
  • Skeptics invoke past disasters (e.g., earlier weight‑loss drugs, rodent thyroid tumors) and unknown long‑term effects.

Conflicts of Interest and Media/Industry Incentives

  • Multiple comments question plastic surgeons’ incentives: they profit from both liposuction and post‑Ozempic skin procedures.
  • The article is criticized as click‑driven, vague on mechanism, and possibly amplifying fears.